Leerink analyst Geoffrey Porges expects Alexion's flagship complement inhibition franchise to remain the dominant, if not only, terminal complement inhibitor on the market. The analyst notes that his research finds that the number of manufacturers with competing programs in early stage development face "significant" technical and market-related challenges to match or surpass Soliris. Porges continues to view Alexion's complement franchise as durable and capable of sustaining revenue growth throughout the mid-term as the company expands into other rare diseases. He reiterates an Outperform rating on the stock and raised his price target on the shares to $211 from $210.